Clinical Trial Update: Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial investigating ruxolitinib-enhanced haploidentical hematopoietic stem cell transplantation for children and young adults with Sickle Cell Disea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: University of Colorado, Denver | Conditions: Sickle Cell Disease, Hematopoetic Stem Cell Transplant | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING